Welcome to the fourth of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?" Transactions involving digital assets are an increasing focus for pharmaceuticals, medical device and medtech companies. In this series, life sciences industry M&A veteran and Sterling Technology board advisor John Easton discusses how these differ from traditional life science deals, and what both acquiror and target should look out for to increase the chances of deal success, mitigate risks, and avoid failure.
Technology targets will likely present challenges to dealmakers who are more comfortable evaluating traditional in-licensing or acquisition transactions with pharmaceutical or biotech companies. How should acquirors successfully conduct due diligence on digital assets and what capabilities do they need? To find out, click below and listen to our latest episode. You can also add the podcast series to one of several apps, such as Apple Podcasts, by clicking the "+ Follow" link.
To learn more, follow this link here to download a copy of the report that accompanies the podcast series.
